Plasma Cell Myeloma News and Research

RSS

Challenges in High Complexity Flow Cytometry

In this interview, Dra. Mª José Marco from the Department of Hematology at Hopsital Dr. Peset talks to News-Medical Life Sciences about high complexity flow cytometry and the challenges they often face.

From Beckman Coulter Life Sciences - Flow Cytometry 24 Sep 2020

$FDA grants accelerated approval to new treatment for refractory multiple myeloma$

FDA grants accelerated approval to new treatment for refractory multiple myeloma

Today, the U.S. Food and Drug Administration granted accelerated approval to Xpovio (selinexor) tablets in combination with the corticosteroid dexamethasone for the treatment of adult patients with relapsed refractory multiple myeloma who have received at least four prior therapies and whose disease is resistant to several other forms of treatment, including at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody.

3 Jul 2019

Data presented at AACR 2015 recognizes value of EKF PointMan technology for assessing lung cancer mutation status

The PointMan EGFR DNA enrichment kit, a novel method for selective amplification of genotype specific sequences.

From EKF Diagnostics 21 Apr 2015

Phase 2 RESONATE-17 study: IMBRUVICA (ibrutinib) improves survival in CLL patients with del 17p

Results from the Phase 2 RESONATE-17 (PCYC-1117) study show IMBRUVICA (ibrutinib) was associated with an 82.6 percent investigator-assessed overall response rate (ORR; the primary endpoint) and a 79 percent progression-free survival (PFS) rate at 12 months in people living with relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have a genetic mutation known as deletion 17p (del 17p).

9 Dec 2014

Study: REVLIMID and dexamethasone for high-risk smoldering multiple myeloma reduce risk of disease progression

Celgene International Sàrl (NASDAQ: CELG) announced that data evaluating combination therapy REVLIMID® (lenalidomide) and dexamethasone in patients with high-risk asymptomatic smoldering multiple myeloma were presented during the American Society of Hematology's annual meeting. The study reported REVLIMID and dexamethasone prolonged time to progression.

6 Dec 2010

Revlimid receives approval in Switzerland for treatment of multiple myeloma

Celgene International Sarl has announced that it's oral cancer drug, Revlimid (lenalidomide) has been granted approval by the Swiss Agency for Therapeutic Products (Swissmedic) for use in combination with dexamethasone as a treatment for patients with multiple myeloma who have received at least one prior therapy.

5 Sep 2007

Revlimid clinical data in newly diagnosed multiple myeloma presented

Celgene Corporation announced today that data evaluating clinical results on Revlimid (lenalidomide) as a new therapeutic approach for patients with newly diagnosed multiple myeloma (MM) was presented at the American Society of Hematology 46th Annual Meeting in San Diego.

7 Dec 2004